Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMAZING: Effect of Glimepiride, Vildagliptin, Pioglitazone and Canagliflozin After Metformin Failure in Type 2 Diabetes
NCT02142309Phase 4Unknown
- Sponsor
- University of Campania Luigi Vanvitelli
- Start
- Oct 2005
- Primary completion
- Oct 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised trial of glimepiride, vildagliptin, pioglitazone and canagliflozin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by University of Campania Luigi Vanvitelli. Primary endpoint: Time to primary failure with a HbA1c value >7% at 6 years. Status: unknown.
02
Drugs
glimepiridevildagliptinpioglitazonecanagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02142309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02142309.